Objective: Epilepsy is a common neurologic disorder resulting in spontaneous, recurrent seizures. About 30-40% of patients are not responsive to pharmacologic therapies. This may be due to the differences between individual patients such as etiology, underlying pathophysiology, and seizure focus, and it highlights the importance of new drug discovery and testing in this field. Our goal was to determine the efficacy of lacosamide (LCM), a drug approved for the treatment of focal seizures, in a model of generalized epilepsy with cortical dysplasia (CD). We sought to compare LCM to levetiracetam (LEV), a drug that is currently used for the treatment of both partial and generalized epilepsy and to test its proficiency. Methods: Pregnant rats were irradiated to produce pups with malformed cortices in a model of CD, which will be referred to as the "first hit." Adult animals, developed normally (NL) and irradiated (XRT), were surgically implanted with electroencephalography (EEG) electrodes. Baseline EEG was recorded on all rats prior to pretreatments with either LCM, LEV, or placebo (PBO). After 30 min, all rats were injected with a subconvulsive dose of pentylenetetrazole (PTZ), a c-aminobutyric acid receptor A (GABA A ) antagonist used to provoke generalized seizures as a "second hit." Results: LCM and LEV were both effective against seizures induced by PTZ. XRT rats had a higher seizure incidence with longer and more severe seizures than NL rats. Seizure duration was decreased with both LCM and LEV in all animals. In XRT rats, there was a significant reduction in acute seizure incidence and severity with both LCM and LEV after PTZ injection. Significance: Our results suggest that LCM could be used as a potential treatment option for generalized epilepsy with CD as the underlying pathology.
Epilepsy is the fourth most common neurologic disorder in the United States and it affects >50 million people worldwide. 1, 2 It is estimated that one in 26 people will develop epilepsy during their lifetime. 3 Even with advanced therapies, 30-40% of patients are not responsive to current pharmacologic treatments. 4 Cortical dysplasia (CD) is a pathologic malformation of the cortical architecture, which causes the involved parts of the brain to be highly excitable. 5 Patients with CD are often unresponsive to current pharmacologic treatment; therefore, it is imperative to investigate new therapies to treat the seizures within this abnormal pathology. Clinical trials have demonstrated the efficacy of lacosamide (LCM) in focal seizures. 6, 7 However, little is known about LCM's effect on generalized seizures, or its effect on dysplastic cortex.
Lacosamide ((R)-2-acetamido-N-benzyl-3-methoxypropionamide) is a functionalized amino acid developed for the treatment of epilepsy. 8, 9 Although the exact antiepileptic mechanism of LCM in clinical use has not been fully elucidated, the agent is shown to act on the slow inactivation of voltage-gated sodium channels in vitro. [10] [11] [12] This mechanism of action is innovative as a therapy for generalized seizures, because current antiepileptic drugs (AEDs) including carbamazepine, phenytoin, and lamotrigine target sodium channels affecting fast inactivation. 10, 13 LCM also has a fast absorption rate with steady-state concentrations achieved shortly on administration.
14 It has a half-life of 13 h and is excreted in the urine. 12 In addition, LCM reveals minimal protein binding and limited or no interaction with cytochrome P450 isoenzymes, making it unlikely to interact with other drugs.
14 Together, the novel mechanism of action of LCM and its safety make it an attractive candidate for the treatment of generalized epilepsy. [10] [11] [12] 14 We sought to examine the effect of LCM in an established animal model of symptomatic generalized seizures, with and without CD. In a rodent model of multifocal CD, rats are irradiated in utero to induce the development of this proepileptic substrate CD. 15 Adult CD rats exhibit decreased thresholds to seizures provoked by a "second hit" upon administration of the proconvulsant drug pentylenetetrazole (PTZ). To assess the efficacy of LCM on generalized seizures, we also treated rats with levetiracetam (LEV), a medication with a distinctly different mechanism of action that shows clear efficacy in generalized epilepsies. 16, 17 Although LEV acts on synaptic transmission, it is shown to have no effect on sodium currents, making it a good alternative drug for comparison.
Methods

Animals
In utero irradiation for a model of cortical dysplasia
Six timed-pregnant Sprague-Dawley rats were irradiated at day E17 as described previously. 15, 18, 19 Day 0 (or E0) was considered when the vaginal plug was detected. Pregnant rats were individually contained in a perforated plastic box and placed one at a time into a Shepherd Irradiator containing a 4,000 Ci cesium-137 source (Shepherd and Associates, San Fernando, CA, U.S.A.). Rats were exposed to 145 cGy of radiation over a duration of approximately 2 min. Six additional timed-pregnant rats were unexposed and their pups were used as age-matched controls. Irradiated rats with CD are identified throughout the text as XRT, and nonirradiated control rats are identified as NL. Date of birth usually occurred on E22 which was considered postnatal day 0 (PND0). A time line of the experimental procedures is depicted in Figure 1 .
Stereotaxic electrode implantation
A total of 67 adult rats (PND55) were used in this study. XRT and NL rats were divided into eight groups, and received treatment of either no AED or PTZ (+No Drug), saline only (+PBO), levetiracetam (+LEV), or lacosamide (+LCM): XRT +No Drug, n = 3; XRT +PBO, n = 10; XRT +LEV, n = 10; XRT +LCM, n = 10; NL +No Drug, n = 3; NL +PBO, n = 11; NL +LEV, n = 10; and NL +LCM, n = 10. All rats were implanted with epidural EEG recording electrodes. Surgical implantation was performed under 3-5% isoflurane anesthesia. Rats were restrained in a Kopf stereotaxic frame (David Kopf Instruments, Tujunga, CA, U.S.A.) and six epidural screw electrodes (Small part Inc, Miami Lakes, FL, U.S.A.) were implanted: one reference electrode above the frontal sinus, a backup reference above the cerebellum, and two in the frontal and the parietal bones bilaterally. Electrodes were connected to a plastic plug (43020-0801, Heilind Electronics, Wilmington, MA, U.S.A.) and fixed to the skull with dental cement (Hygenic repair resin; Hygenic, Akron, OH, U.S.A.). Animals were given postoperative analgesics (acetaminophen and buprenorphine) and allowed 72 h of recovery prior to experiments.
Video-EEG recording
All rats were recorded for a 24-h period with continuous video-electroencephalography (EEG) monitoring. Rats were placed in a custom-made, electrically shielded box with tethered EEG harness and a digital video camera. The EEG harness was connected to a pendulous electroslip ring (MRS 35-06P; MAET GIKEN, Tokyo, Japan), which allowed for artifact-free recording while animals were moving. Real-time EEG and video data with five channels per rat was recorded with a Nihon Kohden system (Nihon Kohden America Inc., Irvine, CA, U.S.A.). The acquisition sampling rate was set at 100 Hz, with a low-frequency filter setting of 7 Hz and high-frequency filter of 70 Hz. Animals were unrestrained and had access to food and water ad libitum during the recording session. Following 1 h of baseline EEG recording, rats were treated with an injection of the vehicle, 9% sterile saline solution (PBO), LEV (60 mg/kg, i.p.) supplied by UCB Pharma as a purified product and diluted in 9% sterile saline 20 or LCM (25 mg/kg, i.p.) supplied by UCB Pharma as a purified product and diluted in 9% sterile saline, 21 triggered a severe seizure in almost all XRT rats (without AED treatment), but only half of normal rats, since the XRT rats have a decreased seizure threshold. Rats were recorded for 24 h after injection.
EEG and video analysis
Digitized EEG was reviewed using NeuroWorkbench software (Nihon Kohden America Inc.). EEG signals were reformatted in referential and bipolar montages. Recorded sessions were analyzed by visual inspection for epileptiform activity including EEG seizure onset and repetitive spiking. The EEG seizures were defined as repetitive spikes with interruption of the background activity for 10 s or longer. All EEG seizures were confirmed using simultaneous video recordings. EEG seizures were analyzed for latency from PTZ injection to first EEG seizure and the duration of EEG seizure. Seizure severity was assessed behaviorally using a standard scale, 22 which divides PTZ-induced seizures into those having minimal versus major manifestations. No changes in behavior would receive a score of 0, abnormal behavior (sniffing, intensive washing, orientation) received 0.5, isolated myoclonic jerks was given a score of 1, atypical (unilateral or incomplete) minimal (clonic) seizures were scored as 2, fully developed minimal seizures were scored 3, generalized tonic-clonic seizures with a suppressed tonic phase received a score of 4, and fully developed tonic-clonic seizures were scored at 5.
Histology
To confirm CD in the XRT rats, all rats were sacrificed 24 h after PTZ injection. Rats were deeply anesthetized with ketamine (100 mg/kg, i.p.) and perfused transcardially with 4% paraformaldehyde (PFA). Brains were harvested and fixed in 4% PFA for 24 h and then transferred to 30% sucrose solution for 48 h. Brains were frozen and cut into 30-lm coronal sections with a cryostat (Leica CM-1850; Heidelberg, Germany). Slices were mounted to glass microscope slides and stained with cresyl violet (CV). Slides were blindly examined for presence of CD (Fig. 2) as established previously. 23 
Statistical analysis
Statistical analyses were performed using JMP Pro 9.0.0 Software (SAS Institute Inc., Cary, NC, U.S.A.). A chi-square test was run on seizure incidence and a Wilcoxon rank-sum test was run on all ordinal data, such as behavioral scores. Independent groups t-tests were run on all numeric data, such as seizure latency and duration. Results were considered statistically significant with pvalues <0.05. Comparisons were made between all eight groups based on numeric data gathered for seizure latency and duration, as well as ordinal data from seizure severity as graded by a standard scale, and the time spent in each grade during the seizure.
Results
LCM effectively reduced seizure incidence
Injection of PTZ in the absence of any AED resulted in the highest incidence of seizures in both NL and XRT rats (Table 1) . PTZ injection in XRT rats resulted in higher duration and incidence of seizures in comparison to NL rats. Our data demonstrated that 90% of XRT ÀAED (no LEV or LCM) rats had seizures, whereas only 45% of NL ÀAED rats had seizures with this subconvulsive dose of PTZ. The XRT rats showed significant seizure reduction when treated with either LCM or LEV (p < 0.001). However, there was no difference in seizure incidence between LCM and LEV in the XRT (p = 0.50) or NL rats (p = 0.12), suggesting LCM provides a similar protection against generalized seizures as compared to LEV.
Prolonged seizure duration in CD was shortened with AED treatment
The XRT ÀAED rats had a significantly longer seizure duration than the NL ÀAED rats (p < 0.001). Seizure duration was reduced in both the XRT and NL groups receiving LEV or LCM. A significant difference in seizure duration was not measured in rodents treated with LCM compared to those treated with LEV (Table 1 ). Histologic differences between NL (nondysplastic) and XRT (dysplastic) rats including dyslamination in the cortex and cellular clustering, as well as a burst of cells at CA1 and CA2 (arrows). Epilepsia ILAE Table 1 . Chart of results showing XRT rats with PTZ injection but no AED exhibit the most severe seizures (3.6 behavioral score) with the highest incidence (90% of rats) and longest duration (129 s) Seizure severity was decreased with AED treatment Due to the distribution of the data, animals exhibiting scores of 0-1 were given a seizure grade of 0 (least severe); animals with scores of 2-3 were given a seizure grade of 1 (moderately severe); and animals that scored 4-5 were given a seizure grade of 2 (most severe), and analyzed with a Wilcoxon rank-sum test. Almost all of the untreated (PBO) XRT rats exhibited more severe seizures associated with loss of righting ability. However, XRT rats that had received LCM or LEV, exhibited less severe seizures without losing their righting ability or progressing to generalized tonic-clonic seizures. Myoclonic seizures were seen in both LCM and LEV pretreated groups, although the frequency of these seizures appeared lower in LEV-treated animals. Overall, NL animals had less severe seizures, as compared to XRT animals, and both LEV and LCM reduced seizure severity (Fig. 3) .
Discussion
Our results show that LCM decreased generalized seizures in CD, suggesting that its novel mechanism of action may be effective in patients with abnormal pathologies that might not respond to current pharmacologic therapies. We compared LCM, a newer AED used to treat partial epilepsy, with LEV, a drug commonly used to treat both partial and generalized epilepsy (adjunctive therapy). Our results show that treatment with LCM impedes acute generalized convulsive seizures induced by a "second-hit," in a rat model of in utero radiation-induced CD. Consistent with our previous studies, XRT rats exhibited longer and more severe seizures after PTZ injection compared to control rats. 19, 23 Seizure incidence, duration, and severity were decreased with LCM treatment as compared to placebo treatment, showing that LCM is effective as monotherapy against seizures in this preclinical model of generalized epilepsy. Both LCM and LEV inhibited progression to more severe seizures, during which the rodent lost its righting ability. This was observed in both NL and XRT rats. These results suggest that LCM may be a candidate for treatment of medically intractable epilepsy caused by underlying pathologic abnormalities such as CD.
The effects of LCM on generalized epilepsy have remained inconclusive. Research on the efficacy of LCM showed that it was effective against seizures induced by maximal electroshock test (MES) in rats and mice, soundinduced seizures in the Frings mouse, and hippocampal kindling of partial seizures. 21 However, LCM was ineffective against subcutaneous injections of PTZ, bicuculline, and picrotoxin. 21 LCM has a unique modulatory mechanism of action on the voltage-gated sodium channel shown by shifting of the slow inactivation curve toward hyperpolarization, thereby enhancing the fraction of channels in the slow inactivation state, and thus reducing seizure frequency and providing a possible mechanism of action that is more amendable to reducing seizures in drug-resistant epilepsies than other current AEDs. 10, 21, [24] [25] [26] [27] In addition, LCM does not affect synaptic transmission machinery, which may allow for a reduction in some side effects experienced with other voltage-gated sodium channel antagonists. 28, 29 With an alternative anticonvulsant mechanism, LCM may be better suited for some patients than for others, as we show a slightly longer latency with LCM in XRT rats as compared to controls. This was recently reflected in the literature in a case study reporting two women with drug-resistant idiopathic primary generalized epilepsy who were responsive to LCM after failing many other AEDs. 30 Of interest, LCM was also shown to be more effective in a 6 Hz stimulation model of drug-resistant epilepsy than other AEDs including lamotrigine, topiramate, felbamate, and levetiracetam. 21, 31, 32 Taken together, these preclinical studies and the results from our research provide new insight into the efficacy of LCM in treating seizures in those epilepsies complicated by underlying pathologies such as CD. However, further research is required to determine its efficacy in chronic, drug-resistant epilepsy.
LCM has not previously been studied in a rat model of CD with generalized seizures. Our results show for the first time that LCM is efficient in treating generalized seizures induced in normal and XRT rats. However, it is not known if LCM efficiency is specific for treatment in XRT animals. Although our results show that XRT rats have greater improvement with LCM compared to control animals, this could be because XRT rats have more frequent and more severe seizures than control rats with the same PTZ dosage. In addition, this study evaluates only acute drug efficacy, and studies using chronic epilepsy models with continuous drug treatments are necessary. Future studies are needed to understand the possible neuromodulatory functions of LCM, which may uncover the underlying mechanisms involved in epilepsies that are more difficult to treat. Further comparisons with different doses and other medications with different seizure-suppressing mechanisms are warranted. It is important to note that this model of multifocal CD most closely resembles the architecture of type Ic in human focal cortical dysplasia. 33 Therefore, the results from this study may differ in other classifications of CD in humans, especially type II, as the underlying mechanisms are likely very different. Future studies should evaluate the role of LCM within other models of epilepsy to determine its applications and efficacy, as the mechanisms may be different. In conclusion, our study reports the efficacy of LCM on suppressing generalized seizures in both CD and non-CD pathologies. These data support the use of LCM in generalized epilepsy. The results from this preclinical study not only provide preliminary data about the efficacy of LCM in generalized epilepsy syndromes, but also reveal new information about the effect of LCM and LEV on CD, one of the most AED-resistant epilepsy etiologies. 34 However, future studies are necessary to evaluate the efficacy of LCM in humans.
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